Nouscom said it raised an oversubscribed $135 million Series D to advance NOUS-209, its off-the-shelf neoantigen cancer immunotherapy aimed at “cancer interception” in Lynch syndrome carriers. The company said its single global, registration-enabling clinical trial is supported by an FDA Fast Track designation, reflecting early regulatory engagement for the prevention setting. The financing is co-led by M Ventures and Revelation Partners, with new and returning investors including Angelini Industries, the European Investment Bank, and Neva SGR via Intesa Sanpaolo. Nouscom also tied the funding to a near-term clinical readout planned for ESMO, where it will share long-term Phase Ib/II colonoscopy-confirmed outcomes. In the reported ESMO abstract, all evaluable Lynch syndrome carriers who received NOUS-209 remained free of advanced adenomas and colorectal cancer at year one (n=43) and year two (n=17). The data update is positioned as proof-of-concept for intercepting progression rather than treating established malignancy. For investors and clinicians, the move underscores growing interest in prophylactic immunotherapy strategies that can establish durable lesion-free states, particularly in genetically defined high-risk populations.